| Home : November 2018 : November 02, 2018 News : BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC |
BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC |
November 02, 2018
BERGEN, Norway, Nov. 2, 2018 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) announces that the analysis of the first stage of its Phase II clinical trial with bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in...
https://www.prnewswire.com:443/news-releases/bergenbio-to-present-late-breaking-abstract-on-phase-ii-trial-of-bemcentinib-in-combination-with-keytruda-in-advanced-nsclc-at-sitc-300742943.html
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|